Fentanyl effervescent buccal tablets: new formulation. For cancer patients with breakthrough pain: a second buccal formulation with minimal evaluation.
There is no firm evidence that patients with breakthrough cancer pain respond better to fentanyl effervescent buccal than to the "lollipop" formulation.
D000278:Administration, Buccal; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D004304:Dosage Forms; D005060:Europe; D005283:Fentanyl / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009061:Mouth Mucosa; D009369:Neoplasms / Q000188:drug therapy*; D010148:Intractable Pain / Q000188:drug therapy*; D010166:Palliative Care; D017060:Patient Satisfaction; D016032:Randomized Controlled Trials as Topic; D013607:Tablets; D016896:Treatment Outcome
D000701:Analgesics, Opioid; D004304:Dosage Forms; D013607:Tablets; D005283:Fentanyl